Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab.

MLA

Kater, Arnon P., et al. “Long-Term Immune Changes in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Following Treatment with Venetoclax plus Rituximab.” HemaSphere, vol. 8, no. 8, Aug. 2024, p. e146. EBSCOhost, https://doi.org/10.1002/hem3.146.

APA

Kater, A. P., Eichhorst, B. F., Owen, C. J., Jaeger, U., Chyla, B., Lefebure, M., Millen, R., Jiang, Y., Thadani-Mulero, M., Boyer, M., & Seymour, J. F. (2024). Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab. HemaSphere, 8(8), e146. https://doi.org/10.1002/hem3.146

Chicago

Kater, Arnon P, Barbara F Eichhorst, Carolyn J Owen, Ulrich Jaeger, Brenda Chyla, Marcus Lefebure, Rosemary Millen, et al. 2024. “Long-Term Immune Changes in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Following Treatment with Venetoclax plus Rituximab.” HemaSphere 8 (8): e146. doi:10.1002/hem3.146.